Tyvaso Becomes 1st PH-ILD Treatment Approved in US

Tyvaso Becomes 1st PH-ILD Treatment Approved in US

290896

Tyvaso Becomes 1st PH-ILD Treatment Approved in US

Tyvaso (inhaled treprostinil) has become the first treatment approved in the U.S. for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in PH-ILD patients, the company said. “The regulatory approval of Tyvaso, an inhaled treatment, is exciting news both for patients with PH-ILD and the physicians who treat adults living with this serious, life-threatening disease” —…

You must be logged in to read/download the full post.